Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
Esther Natalie Olíva(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Roberto Latagliata(Ospedale di Belcolle), Andrea Kündgen(Heinrich Heine University Düsseldorf), Grazia Sanpaolo(Casa Sollievo della Sofferenza), Francesca Ronco(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Maria Antonietta Aloe Spiriti(Sapienza University of Rome), Maria Grazia D’Errigo(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Giuseppe A. Palumbo(University of Catania), Michael Lauseker(Zimmer Biomet (Germany)), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Irene Santacaterina(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Antonella Poloni(Marche Polytechnic University), Caterina Alati(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Alessandra Ricco(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Antonio Volpe(Azienda Ospedaliera S.Giuseppe Moscati), Ulrich Germing(Heinrich Heine University Düsseldorf), Enrico Balleari(Ospedale Policlinico San Martino)
Cited by 23
Related Papers
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
|Blood|2010|485
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
|Journal of Clinical Oncology|2011|450